One study showed that a cell-based vaccine, Meso-VAX, in combination with the adeno-associated virus (AAV)-IL-12 increased the number of MSLN-specific T cells and the levels of anti-MSLN Abs and enhanced tumor clearance activity in mice [80]. This evidence concerns the gene MSLN and neoplasm.